• The MDinteractive deadline for 2020 MIPS reporting is
    Monday, March 1, 2021.

  • MDinteractive is an approved CMS Qualified Registry for
    2020 and 2021.

  • CMS Publishes 2021 Final Rule. What will it mean for your practice?
    Check out our highlights blog here.

MIPS Measures Relevant to Pathology

  1. Quality - 70% of total score:  Report 6 measures, including one Outcome or other High Priority measure for 12 months on at least 70% of eligible encounters to possibly earn more than 3 points on a measure. Note: Small practices (less than 16 in the practice) can earn 3 points on a measure if at least 1 eligible case is reported.  Information about EMA (what happens if you report less than 6 measures) can be found here. Suggestions for your specialty include, but are not limited, to the following:   
    ID:
    249
    NQF:
    1854
    eMeasure ID:
    High Priority:
    No

    2020 MIPS Measure #249: Barrett's Esophagus

    Percentage of esophageal biopsy reports that document the presence of Barrett’s mucosa that also include a statement about dysplasia

    Measure Type
    • Process
    Specifications
    Specialty
    • Pathology
    ID:
    250
    NQF:
    1853
    eMeasure ID:
    High Priority:
    No

    2020 MIPS Measure #250: Radical Prostatectomy Pathology Reporting

    Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status

    Measure Type
    • Process
    Specifications
    Specialty
    • Oncology
    • Pathology
    ID:
    395
    NQF:
    eMeasure ID:
    High Priority:
    Yes

    2020 MIPS Measure #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)

    Pathology reports based on biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type or classified as NSCLC-NOS with an explanation included in the pathology report

    Measure Type
    • Process
    Specifications
    Specialty
    • Pathology
    ID:
    396
    NQF:
    eMeasure ID:
    High Priority:
    Yes

    2020 MIPS Measure #396: Lung Cancer Reporting (Resection Specimens)

    Pathology reports based on resection specimens with a diagnosis of primary lung carcinoma that include the pT category, pN category and for non-small cell lung cancer (NSCLC), histologic type

    Measure Type
    • Process
    Specifications
    Specialty
    • Pathology
    ID:
    397
    NQF:
    eMeasure ID:
    High Priority:
    Yes

    2020 MIPS Measure #397: Melanoma Reporting

    Pathology reports for primary malignant cutaneous melanoma that include the pT category and a statement on thickness, ulceration and mitotic rate

    Measure Type
    • Process
    Specifications
    Specialty
    • Pathology
    ID:
    440
    NQF:
    eMeasure ID:
    High Priority:
    Yes

    2020 MIPS Measure #440: Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician

    Percentage of biopsies with a diagnosis of cutaneous Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), or melanoma (including in situ disease) in which the pathologist communicates results to the clinician within 7 days from the time when the tissue specimen was received by the pathologist

    Measure Type
    • Process
    Specifications
    Specialty
    • Dermatology
    • Pathology
     
  2. IA: Improvement Activities - 15% of total score:  Attest that you completed up to 2 high-weighted activities or 4 medium-weighted activities for a minimum of 90 days. Groups with 15 or fewer participants or if you are in a rural or health professional shortage area,  attest that you completed 1 high-weighted or 2 medium-weighted activities for a minimum of 90 days.  There are over 100 possible activities to choose from. The following are suggestions only:

Register with MDinteractive